Jeffrey G. Spragens - 07 Dec 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: Director
Signature: /s/ Jeffrey G. Spragens
Issuer symbol: SABS
Transactions as of: 07 Dec 2022
Net transactions value: +$99,999
Form type: 4
Filing time: 09 Dec 2022, 08:02:58 UTC
Previous filing: 23 May 2022
Next filing: 02 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SABS	Common Stock	Award	$99,999	+82,987	+27%	$1.20	394,989	07 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SABS	Warrant (Common Stock)	Award		+82,987			82,987	07 Dec 2022	Common Stock	82,987	$1.08	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

Content

On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.